Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Eric W. Roberts, a director at CalciMedica, Inc. (NASDAQ:CALC), has recently purchased 5,000 shares of common stock at $1.6047 per share, close to the current trading price of $1.62. The total value of the purchase amounted to $8,023. This insider buying comes as the stock has declined 46% over the past six months, though InvestingPro analysis suggests the company is slightly undervalued at its current $22.63M market capitalization.
The transaction, which occurred on July 9, 2025, was reported in a Form 4 filing with the Securities and Exchange Commission. Following this transaction, Roberts directly holds 164,706 shares. Roberts also indirectly holds 37,823 shares by FMTC Custodian - Roth IRA FBO Eric W. Roberts, 49,894 shares by Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA, 10,661 shares By IRA Financial Trust Company CFBO Eric W. Roberts, 356,989 shares by Valence Investments SPV IV, LLC, 66,228 shares by Valence Investments SPV V, LLC and 316,109 shares by Valence Investments SPV VI, LLC.
In other recent news, CalciMedica Inc. has announced the design of its Phase 2 KOURAGE trial for the treatment of acute kidney injury (AKI) with respiratory failure. The trial will involve approximately 150 patients and aims to evaluate the effectiveness of Auxora, with primary endpoints focusing on days alive without ventilator or dialysis support. Preclinical data and previous trials suggest significant potential benefits, with a notable reduction in mortality rates among COVID-19 patients with AKI. Additionally, CalciMedica has appointed Baker Tilly US, LLP as its new independent registered public accounting firm following a merger with Moss Adams LLP. This change was approved by the company’s Board of Directors’ Audit Committee, and there were no disagreements with Moss Adams regarding financial disclosures prior to the merger. CalciMedica has confirmed that no consultations were made with Baker Tilly on accounting matters before the merger. The company expects to receive data from the KOURAGE trial by the end of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.